Research programme: melanin-concentrating hormone receptor 1 antagonists - LigandAlternative Names: MCH programme - Ligand; Melanin-concentrating hormone programme - Ligand
Latest Information Update: 06 Jul 2010
At a glance
- Originator Neurogen Corporation
- Developer Ligand Pharmaceuticals
- Mechanism of Action MCHR1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 06 Jul 2010 Preclinical development is ongoing in USA
- 11 Jan 2008 Neurogen Corporation is considering partnership and/or out-licensing opportunities for this research programme (http://www.nrgn.com)
- 13 Mar 2006 Preclinical development is ongoing